Background
==========

In the case of radical mastectomy or breast conservative therapy (BCT), adjuvant radiotherapy (RT), improves local control \[[@B1]-[@B9]\]. Adjuvant chemotherapy (CT) is equally mandatory for diminishing metastatic recurrences \[[@B10]-[@B12]\].

The optimal sequence of CT and RT remains controversial. The delivery of RT can be planned before or after CT, concurrently, or within 2 cycles of CT (\'\'sandwich\'\' therapy). However, the current standard is CT followed by whole-breast-irradiation (WBI). The delay of CT increased the incidence of spared metastasis \[[@B13]-[@B16]\], and the delay of RT induced more frequent local recurrences \[[@B17]-[@B19]\].

Concurrent treatment shortens the duration of therapy, allows RT and CT to start temporally, and potentially improves local control via the radiation sensitizing effects of CT. Concurrent chemoradiotherapy (CCRT) has successfully been achieved with cyclophosphamide, methotrexate and fluorouracil (CMF) \[[@B20]-[@B22]\]. The concurrent use of taxanes and WBI seems feasible \[[@B23]\].

Anthracycline regimens improve survival in the adjuvant setting \[[@B24]\]. Unfortunately, concomitant use of epirubicin or doxorubicin produced 30% to 44% rate of high grade radiation dermatitis (RD) \[[@B25],[@B26]\], and concurrent mediastinal irradiation with doxorubicin induced intense cardiac dysfunction \[[@B27]\]. This was discouraging the use of anthracyclines and radiation concurrently.

However, in a previous study conducted in our institute we showed that CCRT using anthracycline and WBI produced only 4.5% of ≥ grade 2 RD, and improved the locoregional control over the treatment based on CMF \[[@B28]\]. And recently, in another study, the authors confirmed the feasibility of partial breast irradiation (PBI) with concurrent dose-dense doxorubicin and cyclophosphamide in early breast cancer \[[@B29]\].

The present work, by including more patients, had the objective to confirm our previous results and to support the feasibility and efficiency of concomitant use of anthracycline \[[@B28],[@B30]\]. It was based on the study of a data base of 400 patients treated by radical surgery (mastectomy or breast conservative therapy \[BCT\]) and adjuvant CCRT. We compared the efficacy, and tolerability of two concomitant protocols, the first with anthracycline based regimens and the second with CMF regimen.

Methods
=======

1. Patient selection
--------------------

### Eligibility

From January 2001 to December 2003, 400 women with pathological confirmed breast cancer at stages pT1-T4/pN0-3, without any evidence of metastatic disease, who received complete excision of the primary tumor (mastectomy or BCT) and treated with adjuvant CCRT, were selected at the National Institute of Oncology in Rabat, for investigation.

Two hundred forty four of the cases analyzed in the present study have been the subject of one previous published report \[[@B28]\].

Patient medical records (demographic data, disease stages, histological findings, treatment and outcome) were analyzed retrospectively. Radiological, pathological and surgical reports were reviewed to determine the stage of the disease \[[@B31]\]. The diagnostic instrumental examinations used to stage the patients were chest radiograph, abdominal ultrasound performed in all patients, and bone scan (performed in only 15.2% of the patients \[n = 61\]).

### Exclusion criteria

Metastatic breast cancer or incomplete excision of the primary tumour, and patients treated with sequential chemo-radiotherapy.

2. Treatment planning (Figure [1](#F1){ref-type="fig"})
-------------------------------------------------------

![**Study design**. BCT = breast conservative therapy.](1756-0500-3-247-1){#F1}

The patients from which 84.8% (n = 361) had radical surgery and 15.2% (n = 61) had BCT, were divided into two groups on the basis of CT treatment. In group A the treatment was based on anthracycline and in group B the treatment was based on CMF. The median number of CT cycles delivered concurrently with RT was 2 (ranging from 1 to 5).

Group A (n = 249) received CCRT with anthracycline based regimen and group B (n = 151) received CCRT with CMF regimen.

### Radiotherapy

For 96.5% of patients, RT was delivered to the whole breast or to thoracic wall (99.2% in group A and 92.1% in group B). The other 3.5% received only RT in the lymph node region, this can be explained by the fact that these patients had small tumors (pT1-pT2), and received mastectomy with inadequate axillary dissection. 93.3% of the patients received an additional treatment RT delivered to the regional lymph nodes.

All patients were treated with external beam RT using tangential fields of Co- 60-gamma-Ray. The total delivered dose was 50 Gy, divided as 2 Gy daily fractions. A complementary treatment was given by electrons or by breast brachytherapy (10 to 20 Gy) for 28 patients.

### Chemotherapy

The rational of choice of CT was not precised in the patient files. The use of anthracycline regimen was justified by more aggressive tumors and by the lack of availability of other CT drugs.

Chemotherapy consisted of:

\- In group A: a- intravenous AC60 (doxorubicin 60 mg/m^2^and cyclophosphamide 600 mg/m^2^) on day 1, repeated every 21 days for six courses for 173 patients, b- intravenous FEC75 (5-fluorouracile 500 mg/m^2^, epirubicin 75 mg/m^2^, and cyclophosphamide 500 mg/m^2^) on day 1, repeated every 21 days for six courses for 37 patients and c- intravenous FAC50 (5-fluorouracile 500 mg/m^2^, doxorubicin 50 mg/m^2^, and cyclophosphamide 500 mg/m^2^) on day 1, repeated every 21 days for six courses for 26 patients, and d- Thirteen patient received sequential treatment based on 2 different regimens, the first based on anthracycline and the second based on CMF, repeated every 21 days for six courses (table S1 \[additional file 1\]). The timing of CCRT was summarized in table S1 (additional file 1).

\- In group B: intravenous CMF (cyclophosphamide 500 mg/m^2^, methotrexate 60 mg/m^2^, and 5-fluorouracil 500 mg/m^2^) on day 1, repeated every 21 days for six courses for 151 patients.

### Hormone therapy

Adjuvant 5-year tamoxifen was initiated at the end of the CCRT treatment in patients having positive hormone receptor status.

3. Study endpoints
------------------

We retrospectively compared locoregional recurrence free survival (LRFS), event free survival (EFS), overall survival (OS), and toxicity between 2 therapeutic groups A and B and between the subgroups within A and B. The primary outcomes were LRFS and EFS, and the secondary outcomes were OS and safety.

4. Toxicity evaluation
----------------------

The hematologic toxicity was measured through laboratory tests. Only the highest grades of toxicity were considered in the analysis.

Information about non-hematologic toxicities (dermatitis toxicity, cardiac toxicity, and pulmonary toxicity) was not routinely collected. Only few high grades toxicities (≥grade 2) were noted in our data base. This constitutes a major limitation of our retrospective study.

5. Statistical analysis
-----------------------

LRFS, EFS and OS were calculated from the date of diagnosis (fine needle aspiration, biopsy) or surgery to the date of first documented locoregional relapse, and/or to the date of death and last follow-up.

LRFS was of 2 types: in type 1, the events considered were locoregional and occurred in the breast and/or chest wall and/or regional lymph nodes, with or without concurrent metastatic recurrence; in type 2 (isolated LRFS), the events occurred concurrently with metastatic recurrence were not considered.

The Kaplan-Meier method was used to estimate the rates of LRFS, EFS, and OS \[[@B32]\]. The log-rank-test was used to evaluate the differences between the groups. The distribution homogeneity was analyzed with the Pearson-chi^2^-test for both groups. The p values were based on two sided tests and conducted at a 5% significance level

Univariate and multivariate univariate Cox proportional hazard regression models analysis was used to evaluate the relationship between survival (LRFS, EFS, and OS), treatment regimen (anthracycline vs CMF), and patient characteristics (age, lymph node involvement, tumour volume, tumour grade, hormonal receptor status, number of cycle of concurrent CT) \[[@B33]\]. Candidate prognostic factors for LRFS, EFS, and OS, with a 0.5 level of significance in univariate analysis were entered in a multivariate Cox model.

Statistical evaluation was carried out using SPSS 17.0 statistical software.

6. Subgroup Analyses
--------------------

The first subgroup concerned the patients who received ≥ 2 cycles of concurrent CT (n = 288), and the second subgroup concerned the patients treated with BCT (n = 61).

7. Consent and statement of ethical approval
--------------------------------------------

As the treatment was decided by the medical staff of the centre depending on the availability of drugs in Morocco, oral consent was obtained from the subjects and was approved by the institutional review boards of the National Institute of Oncology Cancer Centre in Rabat

This study was approved by the institutional review boards of the National Institute of Oncology Cancer Centre in Rabat.

This research is in compliance with the Helsinki Declaration

Results
=======

1. Patient characteristics
--------------------------

Median age was 44 years (range: 22 - 69 years) in group A and 46 years (26 - 95 years) in group B.

The distribution of patient characteristics was partly imbalanced. After the analysis of characteristics homogeneity within the two groups, we found more women aged less than 40 years (*P*= .001), more lymph node involvement (*P*= .019) in group A than in group B, and less patients were menopaused in group A. In addition, we found in group B that more patients received more than 1 cycle of CT concurrently with RT (*P*\< .001) (table [1](#T1){ref-type="table"}).

###### 

Demographic, clinical, histological, molecular and treatment characteristics of all patients (n = 400) and analysis of groups homogeneity (Pearson Chi^2^-test)

  Characteristics                                       Group A \[n = 249\] No (%)   Group B \[n = 151\] No (%)   *P*value
  ----------------------------------------------------- ---------------------------- ---------------------------- ----------
  **Age**                                                                                                         
   **\< 40**                                            76 (30.5%)                   25 (16.6%)                   0.001
   **≥ 40**                                             173 (69.5%)                  122 (83.4%)                  
  **Menopausal status**                                                                                           
   **No**                                               178 (71.5%)                  85 (56.3%)                   0.008
   **Yes**                                              60 (24.1%)                   56 (37.1%)                   
   **Unknown**                                          11 (4.4%)                    10 (6.6%)                    
  **Side**                                                                                                        
   **Right**                                            128 (51.4%)                  72 (47.7%)                   0.552
   **Left**                                             120 (48.2%)                  79 (52.2%)                   
   **Bilateral**                                        1 (0.4%)                     0                            
  **Surgery**                                                                                                     
   **Mastectomy**                                       209 (83.9%)                  130 (86.1%)                  0.561
   **BCT**                                              40 (16.1%)                   21 (13.9%)                   
  **Histology**                                                                                                   
   **DIC**                                              231 (92.8%)                  136 (90.1%)                  0.248
   **LIC**                                              12 (4.8%)                    13 (8.6%)                    
   **Other**                                            1                            0                            
   **Unknown**                                          5 (2%)                       2 (1.3%)                     
  **SBR**                                                                                                         
   **I**                                                15 (6%)                      12 (7.9%)                    0.72
   **II**                                               153 (61.4%)                  97 (64.2%)                   
   **III**                                              74 (29.7%)                   38 (25.2%)                   
   **Unknown**                                          7 (2.8%)                     4 (2.6%)                     
  **Hormonal Receptor**                                                                                           
   **ER+/PR+**                                          123 (49.4%)                  84 (55.6%)                   0.205
   **ER+/PR-**                                          31 (12.4%)                   25 (16.6%)                   
   **ER-/PR+**                                          25 (10%)                     12 (7.9%)                    
   **ER-/PR-**                                          65 (26.1%)                   28 (18.5%)                   
   **Unknown**                                          5 (2%)                       2 (1.3%)                     
  **Tumour**                                                                                                      
   **pT1**                                              28 (11.2%)                   21 (13.9%)                   0.867
   **pT2**                                              142 (57%)                    84 (55.6%)                   
   **pT3**                                              63 (25.3%)                   35 (23.2%)                   
   **pT4**                                              12 (4.8%)                    7 (4.6%)                     
   **Unknown**                                          4 (1.6%)                     4 (2.6%)                     
  **pN, axillary**                                                                                                
   **pN0**                                              44 (17.7%)                   42 (27.8%)                   0.009
   **pN1**                                              69 (27.7%)                   46 (30.5%)                   
   **pN2**                                              77 (30.9%)                   47 (31.1%)                   
   **pN3**                                              50 (20.1%)                   13 (8.6%)                    
   **Unknown**                                          9 (3.6%)                     3 (2%)                       
  **Number of cycle of CT delivered with RT**                                                                     
   **1**                                                87 (34.9%)                   25 (16.6%)                   \< 0.001
   **≥ 2**                                              162 (65.1%)                  126 (83.4%)                  
  **Breast/thoracic wall irradiation**                                                                            
   **No**                                               2 (0.8%)                     12 (7.9%)                    \< 0.001
   **Yes**                                              247 (99.2%)                  139 (92.1%)                  
  **Prophylactic supraclavicular fossa radiotherapy**                                                             
   **No**                                               17 (6.8%)                    10 (6.6%)                    0.556
   **Yes**                                              232 (93.2%)                  141 (93.4%)                  
  **Internal mammary radiotherapy**                                                                               
   **No**                                               16 (6.4%)                    9 (6%)                       0.517
   **Yes**                                              233 (93.6%)                  142 (94%)                    
  **Axillary radiotherapy**                                                                                       
   **No**                                               220 (88.4%)                  120 (79.5%)                  0.012
   **Yes**                                              29 (11.6%)                   31 (20.5%)                   

Abbreviations: BCT = breast conservative therapy; SBR = Scarf-Bloom-Richardson; DIC = ductal invasive carcinoma; LIC = lobular invasive carcinoma; ER = estrogen receptor; PR = progesterone receptor

The analysis of characteristics homogeneity within the subgroup of patients (n = 288) treated with ≥ 2 cycles of concurrent CT showed that more patients in the anthracycline subgroup were younger than 40 (*P*= .044) and there was more lymph nodes involvement (*P*= .009) within anthracycline subgroup (table S2 \[additional file 2\]).

Sixty one patients were treated with BCT, 40 of them received anthracycline based CT and the remaining 21 received CMF. The characteristics homogeneity was also analyzed between theses small subgroups (table S3 \[additional file 3\]).

The median delay of CT after surgery was 6.8 weeks (range: 1 to 60 weeks), and the median delay of RT after surgery was 14.8 weeks (range: 2 to 60 weeks). In the 2 groups A and B respectively, 93.6% and 98% of the patients received the 6 courses of CT. All patients in the two groups received 100% of the planned RT dose.

2. Treatment compliance
-----------------------

The hematologic toxicity was determined in 394 cases. The percentage of patients which developed grade 2-3 anemia was 10.1% vs 6.1% in group A and B respectively (chi^2^-test, *P*= .172). Grade 3-4 neutropenia was present in 14.6% of the cases in group A vs 7.6% of cases in group B (chi^2^-test, *P*= .036). Grade ≥ 2 thrombopenia was found in 1.2% of the cases in group A vs 0.7% of the cases in group B (chi^2^-test, *P*= .6).

There was no cardiac toxicity that was clinically detectable in the two arms. The left ventricular fraction ejection (LVFE) was evaluated in only 9 patients (2 patients in the anthracycline group and 7 in the CMF group), and was normal (LVFE ranged between 63% and 87%).

In group A (n = 249), 12 patients (4.8%) had ≥ grade 2 RD toxicity, vs 2 patients (1.3%) in group B (n = 151) (chi^2^-test, *P*= .065).

Six patients in the anthracycline group showed respiratory symptoms (dry cough in 5 patients and chest pain in 1 patient) vs 0 patients in the CMF group (chi^2^-test, *P*= .055).

3. Outcomes
-----------

### 3.1 Outcomes in group A plus group B (n = 400)

#### LRFS (type 1)

After 72.9 months (72.8 for group A, and 73.3 for group B) median follow-up (range: 4.5 - 99 months), loco-regional relapse was developed by 6 patients in the anthracycline group and by 8 patients in the CMF group. The 5 years LRFS rate was equal to 97.1% in group A *vs*94.6% in group B (hazard ratio \[HR\] = 0.454; 95% CI, 0.157 to 1.308; log-rank *P*= .133) (Figure [2A](#F2){ref-type="fig"}).

![**Comparison of the anthracycline group (group A, n = 249) with the CMF group (group B, n = 151) performed in the whole group of patients (n = 400)**: Kaplan-Meier estimates of LRFS when all locoregional relapses were considered (Panel A), LRFS when only the isolated locoregional relapses were considered (Panel B), EFS (Panel C), and OS (Panel D). LRFS = locoregional recurrence free survival; EFS = event free survival; OS = overall survival.](1756-0500-3-247-2){#F2}

#### Isolated LRFS (type 2)

When only isolated locoregional events were considered for the evaluation of LRFS, loco-regional relapse was developed by 3 patients in anthracycline group and by 7 patients in the CMF group. The 5 years LRFS rate was significantly higher in group A (98.7%) than group B *(*95.1%) (HR = 0.258; 95% CI, 0.067 to 0.997; log-rank *P*= .034) (Figure [2B](#F2){ref-type="fig"}).

#### Event free survival

For EFS, the median follow-up period was 71.2 (72.4 in group A and 64.5 in group B) months (range: 4.5 - 99 months). EFS was evaluated in group A + group B, 86 of whom had experienced an event (relapse or death) at the last follow-up (in anthracycline group: 45 of 249; in CMF group: 41 of 151). The 5 years EFS rate was 80.4% in group A *vs*75.1% in group B, a difference which tended to significance (HR = 0.665; 95% CI, 0.455 to 1.016; log-rank *P*= .057) (Figure [2C](#F2){ref-type="fig"}).

#### Overall survival

For OS, the median follow-up period was 74.5 (74.5 for group A and 74.6 for group B) months (range, 4.5 - 106.6 months). Seventy-two patients died, 38 in group A and 34 in group B. The 5 years OS rate was 83.2% in group A vs 79.2% in group B, a difference that was not statistically significant (HR = 0.708; 95% CI, 0.455 to 1.128; log-rank *P*= .143) (Figure [2D](#F2){ref-type="fig"}).

#### Prognostic factors (table [2](#T2){ref-type="table"})

###### 

Factors influencing LRFS, EFS and OS (Cox proportional Hazard Model)

  Analysis using locoregional recurrence free survival (type 1)                                                                                                        
  --------------------------------------------------------------------- ------------------------- --------------------------- -------------- -------- ---------------- --------------
  **Factors**                                                           **Univariate analysis**   **Multivariate analysis**                                            
                                                                        **HR**                    **95% CI**                  ***P*value**   **HR**   **95% CI**       ***P*value**
                                                                                                                                                                       
  **Lymph node involvement: no vs yes**                                 0.794                     0.221 to 2.846              0.717          \-       \-               \-
  **Tumour: pT1-2 vs pT3-4**                                            0.273                     0.095 to 0.787              0.016          0.326    0.11 to 0.963    0.043
  **SBR grade: 1-2 vs 3**                                               0.692                     0.232 to 2.066              0.509          \-       \-               \-
  **ER status: positive vs negative**                                   0.359                     0.125 to 1.036              0.058          0.387    0.13 to 1.157    0.079
  **Age: ≥ 40 vs \< 40**                                                1.288                     0.359 to 4.618              0.697          \-       \-               \-
  **Regimen: anthracycline vs CMF**                                     0.454                     0.157 to 1.308              0.143          0.347    0.114 to 1.053   0.062
  **Number of cycles of CT delivered concurrently with RT: ≥ 2 vs 1**   0.466                     0.223 to 1.987              0.439          0.587    0.244 to 1.414   0.235
                                                                                                                                                                       
  **Analysis using event free survival**                                                                                                                               
                                                                                                                                                                       
                                                                        **Univariate analysis**   **Multivariate analysis**                                            
                                                                        **HR**                    **95% CI**                  ***P*value**   **HR**   **95% CI**       ***P*value**
                                                                                                                                                                       
  **Lymph node involvement: no vs yes**                                 0.406                     0.216 to 0.766              0.004          0.397    0.216 to 0.779   0.006
  **Tumour: pT1-2 vs pT3-4**                                            0.552                     0.356 to 0.855              0.007          0.624    0.392 to 0.993   0.047
  **SBR grade: 1-2 vs 3**                                               0.801                     0.508 to 1.265              0.341          0.971    0.598 to 1.576   0.906
  **ER status: positive vs negative**                                   0.674                     0.438 to 1.038              0.058          0.64     0.404 to 1.015   0.058
  **Age: ≥ 40 vs \< 40**                                                1.183                     0.717 to 1.951              0.511          \-       \-               \-
  **Regimen: anthracycline vs CMF**                                     0.665                     0.435 to 1.016              0.057          0.558    0.354 to 0.879   0.012
  **Number of cycles of CT delivered concurrently with RT: ≥ 2 vs 1**   0.696                     0.445 to 1.089              0.11           0.625    0.39 to 1.002    0.051
                                                                                                                                                                       
  **Analysis using overall survival**                                                                                                                                  
                                                                                                                                                                       
                                                                        **Univariate analysis**   **Multivariate analysis**                                            
                                                                        **HR**                    **95% CI**                  ***P*value**   **HR**   **95% CI**       ***P*value**
                                                                                                                                                                       
  **Lymph node involvement: no vs yes**                                 0.298                     0.137 to 0.651              0.002          0.317    0.144 to 0.697   0.004
  **Tumour: pT1-2 vs pT3-4**                                            0.619                     0.381 to 1.005              0.052          0.719    0.429 to 1.208   0.213
  **SBR grade: 1-2 vs 3**                                               0.694                     0.427 to 1.130              0.142          0.781    0.466 to 1.309   0.347
  **ER status: positive vs negative**                                   0.737                     0.458 to 1.186              0.208          0.714    0.429 to 1.189   0.196
  **Age: ≥ 40 vs \< 40**                                                1.260                     0.723 to 2.197              0.414          \-       \-               \-
  **Regimen: anthracycline vs CMF**                                     0.708                     0.445 to 1.128              0.143          0.603    0.367 to 0.99    0.046
  **Number of cycles of CT delivered concurrently with RT: ≥ 2 vs 1**   0.768                     0.468 to 1.261              0.297          0.713    0.423 to 1.201   0.203

Abbreviations: HR = hazard ratio; CI = confidence interval; SBR = Scarf-Bloom-Richardson; ER = estrogen receptor; CT = chemotherapy; RT = radiotherapy

The proportional hazard model was used because of the non homogeneity of patient characteristics between the two groups A and B, to identify the positive treatment effect of one group over the other, on LRFS (type 1), EFS and OS.

#### -Analysis of prognostic factors using LRFS (type 1)

Univariate analysis showed that the factors influencing LRFS were the tumor size (*P*= .016), with trend toward significance for the ER status (*P*= 0.058) and CT protocol (anthracycline vs CMF) (*P*= .143). Multivariate analysis showed that the factors influencing LRFS were the tumor size (*P*= .043), and trend toward significance for CT protocol (HR = 0.347; 95% CI, 0.114 to 0.1.053; *P*= .062), and ER status (*P*= .079).

#### -Analysis of prognostic factors using EFS

Univariate analysis showed that the factors influencing EFS were the lymph node involvement status (*P*= .004), tumor size (*P*= .007), and trend toward significance for CT protocol (anthracycline vs CMF) (*P*= .057). Multivariate analysis showed that the factors influencing EFS were the lymph node involvement status (*P*= .005), CT protocol (HR = 0.539; 95% CI, 0.344 to 0.846; *P*= 0.012), and tumor size (*P*= .047), trend toward significance for ER status (*P*= .058) and number of cycles delivered concurrently with RT (*P*= .051).

#### -Analysis of prognostic factors using OS

Univariate analysis showed that the factors influencing OS were lymph node status (*P*= .002) and trend toward significance for tumor size (*P*= .052). Multivariate analysis showed that the factors influencing OS was the lymph node status (*P*= .004) and CT protocol (HR = 0.63; 95% CI, 0.401 to 0.991; *P*= .046).

### 3.2 Outcomes in patients who received more than 1 cycle of CT concurrently with RT (n = 288)

The median follow-up period was 73 months, 72 months, and 74 months, for LRFS, EFS, and OS respectively. Two patients developed loco-regional relapse anthracycline subgroup (n = 162) vs 7 patients in CMF subgroup (n = 126). The 5 years LRFS (type 1) rate was equal to 98.7% in anthracycline subgroup *vs*94.5% in CMF subgroup (log-rank *P =*.038) (Figure [3A](#F3){ref-type="fig"}). The 5 years EFS rate was 84.2% in anthracycline subgroup *vs*75.7% in CMF subgroup (log-rank *P*= .026) (Figure [3B](#F3){ref-type="fig"}). The 5 years OS rate was 86.6% in anthracycline subgroup vs 79.8% in CMF subgroup (log-rank *P*= .038) (Figure [3C](#F3){ref-type="fig"}).

![**Panels A, B, and C: Anthracycline (n = 162) compared to CMF (n = 126) in the subgroup of patients treated with ≥ 2 cycles of concurrent CT with RT: Kaplan-Meier estimates of LRFS (Panel A), EFS (Panel B), and OS (Panel C); Panels D, E, and F: Anthracycline (n = 40) compared to CMF (n = 21) in the subgroup of patients treated with BCT (n = 61): Kaplan-Meier estimates of LRFS (Panel D), EFS (Panel E), and OS (Panel F)**. LRFS = locoregional recurrence free survival; EFS = event free survival; OS = overall survival.](1756-0500-3-247-3){#F3}

### 3.3 Outcomes in patients treated with BCT (n = 61)

The median follow-up period was 73 months, 73 months, and 75 months, for LRFS, EFS, and OS respectively. The 5 years LRFS rate (type 1) was equal to 100% in anthracycline subgroup *vs*94.1% in CMF subgroup (log-rank *P =*.049) (Figure [3D](#F3){ref-type="fig"}). The 5 years EFS rate was 94.2% in anthracycline subgroup *vs*84% in CMF subgroup (log-rank *P*= .04) (Figure [3E](#F3){ref-type="fig"}). The 5 years OS rate was 94.2% in anthracycline subgroup vs 84% in CMF subgroup (log-rank *P*= .259) (Figure [3F](#F3){ref-type="fig"}).

Discussion
==========

The main advantages of CCRT are: 1. delivering both treatments of CT and RT at same time; 2. biological synergy effect that can increase the efficacy of the treatment \[[@B34]\]. A CT based on liposomal doxorubicin, paclitaxel and vinorelbine, with concomitant RT in non operable and recurrent disease, was found to be of good efficacy and tolerability \[[@B34],[@B35]\]. Reirradiation with concomitant CT was shown to have positive effect \[[@B34],[@B36]\]. In adjuvant setting, CCRT has successfully been achieved by the concurrent use of CMF or taxanes with WBI \[[@B20]-[@B23]\].

Few prospective studies investigated CCRT using anthracycline regimen. The authors showed high rate of high grade skin toxicity, and more cardiac dysfunction, and concluded that this protocol cannot be used in practice \[[@B25]-[@B27]\]. However, in a recent phase I trial, the authors showed that PBI with concurrent dose dense doxorubicin and cyclophosphamide induced an acceptable hematologic and nonhematologic toxicity profile with likelihood of RD ≥ grade 2 is ≤ 11% \[[@B29]\]. These results were in favor of the use of CCRT based on anthracycline regimen and this is why we suggest the evaluation of concurrent versus sequential therapy in early stage breast cancer using anthracycline and modern radiation techniques. In our previous investigation we evaluated two concurrent protocols administered either with anthracycline regimen or with CMF in adjuvant setting and confirmed the beneficial effect of anthracycline based protocol in locoregional control with acceptable toxicity profile over the CMF \[[@B28]\].

After 74.5 months median follow-up, we found no statistical difference in the OS between the two therapeutic groups A and B, which can be explained by the fact that group A was characterized by poorer prognosis (more lymph node involvement). However, we showed a trend toward significance for EFS in favor of anthracycline (log-rank *P*= .057). In addition, when only the isolated locoregional events were considered, the LRFS at 5 years was significantly higher in group A than group B (98.7% vs 95.3%; log-rank *P*= .034). To confirm the beneficial effect of anthracycline we conducted subgroup analyses. The first subgroup concerned patients treated with ≥ 2 cycles of concurrent CT (n = 288 from A and B) and we showed that LRFS, EFS and OS were statistically higher in the anthracycline based treatment than in CMF. The second sub group concerned patients treated with BCT (n = 61 from A and B) and we showed that LRFS and EFS were statistically higher in anthracycline than in CMF. In addition, using the multivariate Cox proportional hazard regression models analysis, we confirmed that the anthracycline regimen favorably influenced the LRFS (type 1) (*P*= .062), the EFS (*P*= .007), and OS (*P*= .046) (table [2](#T2){ref-type="table"}).

However, in adjuvant setting, it has been demonstrated that anthracycline and taxanes containing regimens decreased relapse and improved survival. Consequently, our results may be explained by the effect of anthracycline regimen and not by the use of CCRT \[[@B24],[@B37]\].

Three recent randomized phase III trials were conducted to compare the sequential protocol to the concomitant protocol. In the first trial, 716 patients were treated by BCT and randomized into 2 groups (ARCOSEIN study) \[[@B38]\]. In the first group, the patients were treated by the FNC protocol (5-fluoro-uracil 500 mg/m2, mitoxantrone 12 mg/m^2^and cyclophosphamide 500 mg/m^2^) with concomitant RT. In the second group, the patients were treated by the FNC protocol followed by RT. Arcangely et al. \[[@B39]\], randomly assigned 206 patients (after quadrantectomy and axillary dissection) to concurrent or sequential treatments using CMF based CT. In the third trial, Rouessé et al. \[[@B40]\], randomly assigned 638 patients with prior breast surgery and positive axillary dissection (from which 416 were BCT) to receive CCRT (FNC protocol) or CT (fluorouracil, epirubicin, and cyclophosphamide protocol) followed by RT. No differences in 5-years LRFS, disease-free survival and OS were observed between the 2 treatment groups in the 3 trials. Nevertheless, in the ARCOSEIN study the authors identified a significant decrease in the risk of locoregional recurrence with CCRT for node-positive patients. Rouessé et al. \[[@B40]\], showed that concurrent treatment has a significantly better locoregional control in node-positive breast cancer after BCT.

In our study we found significantly higher locoregional control of the disease and a trend for a higher rate of 5 years EFS in anthracycline group vs CMF group. And we found a superior effect of concurrent use of anthracycline over CMF in terms of LRFS and EFS in the subgroup of patients treated with BCT. In addition, in the subgroup of patient treated with ≥ 2 cycles of concurrent CT, we confirmed the significant beneficial effect of the anthracycline in terms of LRFS, EFS and OS.

The main limitation of the 3 European trials was the use of CMF protocol and FNC protocol which have a safer toxicity profile when radiation treatment was used without the use of anthracycline and taxane regimens. CMF and FNC are older CT regimen used in the past; however more recently anthracyclines and taxanes containing regimens have become standard, and are demonstrated to have improved survival and local recurrence outcomes.

In ARCOSEIN study, moderate acute locoregional toxicities were found in the concomitant arm. Rouessé et al. \[[@B40]\] presented more frequent grade 2 skin toxicities in the concomitant arm, and more subclinical LVFE events at 1 year. In our study we showed more haematologic toxicity when the treatment was based on anthracycline with significantly more grade 3-4 neutropenia. Grade 2-3 anemia and grade ≥ 2 thrombopenia were more frequent in anthracycline group but the differences were not significant.

In our study, we found more respiratory symptoms and high grade (≥ grade 2) RD toxicity (4.8% vs 1.3%) in anthracycline group versus CMF group. We note however that dermatitis toxicity was not routinely evaluated like other adverse events as we would expect much higher dermatitis rates with concurrent taxane/radiation.

Our retrospective study showed different limitations, because it implicated potential bias in the choice of treatment. In addition to the lack of cardiac toxicity evaluation which constituted the major limitation (only 2% \[n = 9\] had assessment of cardiac function via LVEF measurement). However, 50% of the cases were left-sided breast cancers and would probability induce a high risk of cardiac toxicity.

Conclusion
==========

From the present 5 years nonrandomized investigation we concluded that the treatment based on anthracycline and concurrent RT reduced breast cancer relapse rate including locoregional relapses and significantly improved LRFS, EFS and OS in the patients receiving more than 1 cycle of concurrent CT. In multivariate analysis we confirmed that the anthracycline regimens had a positive effect on LRFS, EFS and OS. There were more hematologic and non hematologic toxicities in the anthracycline group. Anthracyclines and WBI cannot be administered concurrently before further investigations to determine efficacy and safety of anthracycline based treatment.
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RT: radiotherapy; CT: chemotherapy; WBI; whole-breast-irradiation; CCRT: concurrent chemoradiotherapy; RD: radiation dermatitis; PBI: partial breast irradiation; CMF: cyclophosphamide 500 mg/m^2^, methotrexate 60 mg/m^2^, and 5-fluorouracil 500 mg/m^2^; EFS: event free survival; OS: overall survival; LRFS: locoregional recurrence free survival; AC60: doxorubicin 60 mg/m^2^and cyclophosphamide 600 mg/m^2^; FEC75: 5-fluorouracile 500 mg/m^2^, epirubicin 75 mg/m^2^, and cyclophosphamide 500 mg/m^2^; FAC50: 5-fluorouracile 500 mg/m^2^, doxorubicin 50 mg/m^2^, and cyclophosphamide 500 mg/m^2^; BCT: breast conservative therapy; LVFE: left ventricular fraction ejection; FNC: 5-fluoro-uracil 500 mg/m2, mitoxantrone 12 mg/m2 and cyclophosphamide 500 mg/m2.
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